SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Exelixis, Inc. (Nasdaq:EXEL) announced today that data from clinical trials of the company’s investigational compounds XL184, XL147, XL765, XL228, and XL281 will be presented at the 2009 American Society of Clinical Oncology (ASCO) Annual Meeting, which will be held from May 29 to June 2, 2009 in Orlando, Florida. Interim data from an ongoing phase 2 clinical trial of XL184 in patients with progressive glioblastoma multiforme in first or second relapse will be described in three poster presentations. Interim data from ongoing phase 1 clinical trials of XL147, XL765, and XL281 in patients with advanced solid tumors, and XL228 in patients with advanced solid tumors or hematologic malignancies will be described in four separate oral presentations. Exelixis is co-developing XL184 with Bristol-Myers Squibb Company and has out-licensed XL281 to Bristol-Myers Squibb Company for further development, but continues to conduct the ongoing phase 1 trials.
